Bioceres Crop SolutionsBIOX
About: Bioceres Crop Solutions Corp is a fully-integrated provider of crop productivity solutions, including seeds, seed traits, seed treatments, biologicals, high-value adjuvants and fertilizers. The company has developed a multi-discipline and multi-product platform capable of providing solutions throughout the entire crop cycle, from pre-planting to transportation and storage. The business divisions consist of crop protection, seed and integrated products, and crop nutrition. The company derives majority of its revenue from the crop protection division. Its product includes fertilizers, inoculants, adjuvants, crop protection solutions and seeds.
Employees: 790
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
0.82% more ownership
Funds ownership: 19.64% [Q1] → 20.46% (+0.82%) [Q2]
0% more funds holding in top 10
Funds holding in top 10: 3 [Q1] → 3 (+0) [Q2]
0% more repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 13
4% less funds holding
Funds holding: 50 [Q1] → 48 (-2) [Q2]
8% less capital invested
Capital invested by funds: $156M [Q1] → $144M (-$12M) [Q2]
29% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 7
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $92K
Research analyst outlook
5 Wall Street Analysts provided 1 year price targets over the past 3 months
5 analyst ratings
Canaccord Genuity Austin Moeller 25% 1-year accuracy 7 / 28 met price target | 66%upside $12.50 | Buy Maintained | 11 Sept 2024 |
Roth MKM Scott Fortune 40% 1-year accuracy 4 / 10 met price target | 73%upside $13 | Buy Maintained | 11 Sept 2024 |
Lake Street Ben Klieve 38% 1-year accuracy 3 / 8 met price target | 73%upside $13 | Buy Maintained | 11 Sept 2024 |
Oppenheimer Kristen Owen 55% 1-year accuracy 6 / 11 met price target | 113%upside $16 | Outperform Maintained | 11 Sept 2024 |
Canaccord Genuity Austin Moeller 25% 1-year accuracy 7 / 28 met price target | 126%upside $17 | Buy Assumed | 19 Jul 2024 |
Financial journalist opinion
Based on 3 articles about BIOX published over the past 30 days